日本已对诺华制药 (NovartisPharma)公司的口服抗真菌药兰美抒 (Lamisil,特比萘芬 )发出警告 ,修订说明书的内容涉及可能造成肝脏疾病和肝功能损害 ,包括黄疸和肝炎。以上症状主要发生在服药治疗的前两个月 ,在这期间 ,通常建议每月进行药物监测 ,以后则要求进行定期性药物监测 Japan has warned Novartis Pharma, the oral antifungal drug Lamisil, that the revised specification addresses possible liver damage and liver damage, including jaundice and hepatitis. The above symptoms occur mainly during the first two months of medication treatment, during which time it is usually advisable to monitor the drug monthly and thereafter to require periodic drug monitoring